Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtech Makes Headway In EU HTA Debate, But More Concessions Sought

Executive Summary

The European Parliament adopted legislation that would establish an EU-wide system for joint clinical health technology assessments including amendments supported by the device industry. But companies are looking to make the plan less prescriptive when it moves to the EU Council.

You may also be interested in...



EU Council Takes Only Small Steps Toward Consensus On HTA Regulations

EU member state have several concerns about the European Commission’s plans for improving cooperation on health technology assessments, making it difficult for the Council of the EU to reach a common position on the proposals.

When Will EU Commission, Member States React To Calls For Extending Regulation Deadlines?

The EU medtech sector, seeing itself heading for a crisis, is hoping the authorities will imminently extend deadlines for the Medical Device and IVD Regulations. What more do we know after last week's crucial Medical Device Coordination Group meeting?

Long Hold Up Anticipated In Council of EU As Member States Battle Over HTA Proposal

Highly divergent views among member states on the European Commission's proposal for a Health Technology Assessment Regulation are likely to lead to delays as ministers struggle to agree on a revised text.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT123380

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel